Potential of microRNA based diagnostics and therapeutics in glioma: a patent review

References

• Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205(12):613–621.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Actaneuropathologica. 2016;131(6):803–820.
   Google Scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772.
   PubMed Web of Science ®Google Scholar
• Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207–212.
   PubMed Web of Science ®Google Scholar
• Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. Codon Publications; 2017. p. 143–153
   Google Scholar
• Alifieris C, Trafalis DT. Glioblastomamultiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Yang JX, Rastetter RH, Wilhelm D. Non-coding RNAs: an introduction. In: Non-coding RNA and the reproductive system. Dordrecht: Springer; Wilhelm D, Bernard P, editors. 2016. p. 13–32
   Google Scholar
• Simonson B, Das S. MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem. 2015;15(6):467–474.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liu J, Quan J, et al. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis. Cancer Sci. 2018;109(9):2651–2659
   PubMed Web of Science ®Google Scholar
• Wang B-C, Jie M. Role of microRNAs in malignant glioma. Chin Med J (Engl). 2015;128(9):1238.
   PubMed Web of Science ®Google Scholar
• Mondal I, Sharma S, Kulshreshtha R. MicroRNA therapeutics in glioblastoma: candidates and targeting strategies. In: AGO-driven non-coding RNAs. Elsevier; 2019. Mallick B, editor. p. 261–292
   Google Scholar
• Geretto M, Pulliero A, Rosano C, et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 2017;7(6):1350–1371
   PubMed Web of Science ®Google Scholar
• Besse A, Sana J, Fadrus P, et al. MicroRNAs involved in chemo-and radioresistance of high-grade gliomas. Tumor Biol. 2013;34(4):1969–1978.
   PubMedGoogle Scholar
• Okada H, Kohanbash G, Lotze MT. MicroRNAs in immune regulation—opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010;42(8):1256–1261.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974.
   PubMed Web of Science ®Google Scholar
• Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9(1):306.
   PubMedGoogle Scholar
• Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010;10(3):297–308.
   PubMed Web of Science ®Google Scholar
• Chin LJ, Slack FJ. A truth serum for cancer—microRNAs have major potential as cancer biomarkers. Cell Res. 2008;18(10):983–984.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao H, Gao Y, et al. Secretory miRNAs as novel cancer biomarkers. BiochimicaetBiophysicaActa (Bba)-rev Cancer. 2012;1826(1):32–43.
   PubMed Web of Science ®Google Scholar
• Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010;10(5):543–550.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Sharma G, et al. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132–143.
   PubMedGoogle Scholar
• Zou C, Li D, Lai L, et al. Application of miRNA-29a compound as brain glioma marker. 2011. (CN102031308A)
   Google Scholar
• Zou C, Li D, Lai L, et al. Application of miRNA-34c compound as brain glioma marker. 2011. (CN102031309A)
   Google Scholar
• Zou C, Li D, Dong D, et al. Application of micro ribonucleic acid (miRNA)-219 compound as marker of brain glioma. 2011. (CN102041316A)
   Google Scholar
• Li G, Minghua W, Tang H, Wu M, et al. Application of miR-182 as glioma generating molecular marker and detective reagent kit thereof. 2012. (CN101792793B)
   Google Scholar
• Min D, Li G, Liu X, et al. Application and detection kit of human miR-183/96/182 cluster. 2013. (CN102424843B)
   Google Scholar
• Keller A, Markus B. Complex sets of miRNAs as non-invasive biomarkers for glioblastoma. 2013. (WO2012089753)
   Google Scholar
• Somasundaram K, Aliga S, Rao M, et al. MicroRNAs (miRNA) as biomarkers for diagnosing different grades of gliomas and pathways of glioma progression. 2014. (US8637241B2).
   Google Scholar
• Chunping J, Junhua W. MicroRNA molecular marker for diagnosing glioma and application of microRNA molecular marker. 2015. (CN104313171A)
   Google Scholar
• Chiou S-H, Chiou G-Y. MicroRNA as a cancer progression predictor and its use for treating cancer. 2015. (US9107934B2).
   Google Scholar
• Shi Y, Lang M-F, Zhao C. Differentially expressed microRNA molecules for the treatment and diagnosis of cancer. 2016. (US9315809B2).
   Google Scholar
• Kolesnikov N, Titov S, Akhmerova L, et al. Method for differential diagnosis of gliomas of human brain. 2016. (RU2583871C1)
   Google Scholar
• Berger F, Issartel J, Atifi-Borel M, et al. Use of miRNAs as biomarkers for diagnosing gliomas. 2017. (EP2510122B1)
   Google Scholar
• Zollo M. Use of microRNA-199b-5p in medical and diagnostic field. 2017. (EP2411515B1).
   Google Scholar
• Krichevsky AM, Teplyuk N, Kesari S, et al. Diagnosing and monitoring CNS malignancies using microRNA. 2018. (US10100367B2)
   Google Scholar
• Zaraisky IM, Sazanov AA, Seliverstov RY, et al. Method of diagnostics and monitoring of course of cerebral gliomas. 2018. (RU2656182C1)
   Google Scholar
• Kim G-H, Kim G, Kim S, et al. Composition for diagnosing recurring glioblastoma multiforme and method for diagnosing same. 2019. (US10266898B2)
   Google Scholar
• Gang L, Qian M, Wang S, et al. Application of miR-1246 and/or TERF2IP in diagnosis and treatment of glioma. 2019. (CN109762903A)
   Google Scholar
• Gang L, Guo Q, Han L, et al. Cerebrospinal fluid exosome miRNA marker related to glioma and application of cerebrospinal fluid exosome miRNA marker. 2019. (CN110129445A)
   Google Scholar
• Rui Y, Zhongzheng S, Gang L, et al. Molecular marker for diagnosing or treating glioma and applications thereof. 2019. (CN109609653B)
   Google Scholar
• Somasundaram K, Srinivasan S, Patric IRP, et al. Method for predicting survival of glioblastoma patient using a ten-miRNA signature.2012. (WO2012114189A1)
   Google Scholar
• Shaw L, Alder J, Tumilson C. Detection of brain cancer. 2019. (EP3019627B1).
   Google Scholar
• Oldenhuis CNAM, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946–953.
   PubMed Web of Science ®Google Scholar
• Tao J, Wei Z. Molecular marker associated with temozolomide for treating glioblastoma. 2013. (CN102329860B).
   Google Scholar
• Zihuang L, Chang Z, Lue Z. Application of microRNA in exosome to evaluation of radiation therapy effect of brain glioma. 2019. (CN110616262A)
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chao T, Li R, et al. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med. 2009;87(1):43–51.
   PubMed Web of Science ®Google Scholar
• Hui W, Yuntao L, Lun L, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PloS One. 2013;8(1):e54932.
   Web of Science ®Google Scholar
• Godlewski J, Bronisz A, Nowicki MO, et al. microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle. 2010;9(14):2814–2820.
   PubMed Web of Science ®Google Scholar
• Ling N, GU J, LEI Z, et al. microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncol Rep. 2013;30(5):2111–2118.
   PubMed Web of Science ®Google Scholar
• Mourad PD, Farrell L, Stamps LD, et al. Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma. Surg Neurol. 2005;63(6):511–519.
   PubMedGoogle Scholar
• Matzuk MM, Creighton C, Yu Z, et al. MicroRNA miRNA-31 as a therapeutic approach for the treatment of cancer. 2011. (WO2011047147A1)
   Google Scholar
• Gaur AB, Israel MA. MicroRNA-21 antagonists and its target PDCD4 for use in the treatment of a glioma. 2012. (US8106028B2).
   Google Scholar
• Gaur AB, Israel MA. MicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma. 2014. (US8778903B2).
   Google Scholar
• Chunfa D, Chao S, Chen W, et al. miRNA simulant inhibiting gene expression and proliferation of human cell division cyclin 42 gene as well as expression vector and application thereof. 2014. (CN103898117A)
   Google Scholar
• Yanchun D, Li W. miRNA (ribonucleic acid) with neuroglioma inhibition function, vector built by same and application. 2014. (CN104232647A)
   Google Scholar
• Chunping J, Junhua W. Application of microRNA-29a in preparation of drugs for treating neuroglioma. 2015. (CN104399088A)
   Google Scholar
• Peruzzi F, Jeansonne D. Use of an miRNA to reduce proliferation of a cancer cell. 2019. (US10308939B2)
   Google Scholar
• Shiro O, Okun O, Daisuke Y et al. microRNA with glioma formation inhibitory action. 2017. (JP6073775B2)
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-133a antisense nucleic acid and application thereof. 2012. (CN102080086B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-193b antisense nucleotide and application thereof. 2013. (CN102080085B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-149 antisense nucleotide and application thereof. 2013. (CN102080083B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-1826 antisense nucleic acid and application thereof. 2013. (CN102382825B).
   Google Scholar
• Kan D, Nan D, Jie L et al. HumanmiR-485-5p antisense nucleic acid and application thereof. 2013. (CN102031256B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR-1825 antisense nucleic acid and application thereof. 2013. (CN102140466B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR (microRNA)-1233 antisense nucleic acid and application thereof. 2013. (CN102140469B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-515-5p antisense oligodeoxynucleotide and applications thereof. 2013. (CN102382823B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR-365 antisense nucleic acid and application thereof. 2013. (CN102140467B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-129* antisense nucleic acid and applications thereof. 2013. (CN102080082B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-125a-5p antisense nucleotide and application thereof. 2013. (CN102080084B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Antisense nucleic acid of human miR-223 and applications of antisense nucleic acid. 2013. (CN102031255B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-1260 antisense nucleic acid and application thereof. 2013. (CN102140462B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR-1249 antisense nucleic acid and application thereof. 2013. (CN102140465B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR-1236 antisense ribonucleic acid and application thereof. 2013. (CN102140470B).
   Google Scholar
• Kan D, Chunxiao D, Jie L et al. Human miR-1238 antisense nucleic acid and applications thereof. 2013. (CN102140464B).
   Google Scholar
• Kan D, Nan D, Jie L et al. Human miR-150 antisense nucleic acid and application thereof. 2014. (CN102031254B).
   Google Scholar
• Kan D, Jie L, Xiaokun S et al. Antisense oligodeoxyncleotide of human miR-484 and application thereof. 2015. (CN102643807B).
   Google Scholar
• Kan D, Jie L, Xiaokun S et al. Antisense oligonucleotide for human miR-431 and application thereof. 2015. (CN102643814B).
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-504 and its application. 2015. (CN102643813B)
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-1229 and its application. 2015. (CN102643811B)
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-299-5p and its application. 2015. (CN102643810B)
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-1539 and its application. 2016. (CN102643808B)
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-1274b and its application. 2016. (CN102643809B)
   Google Scholar
• Jie L, Kan D, Zhang P et al. Antisense human miR-1227 and its application. 2016. (CN102643812B)
   Google Scholar
• Kan D, Peizuo Z, Jie L et al. Antisense human miR-1913 and its application. 2016. (CN102643806B).
   Google Scholar
• Kan D, Peizuo Z, Jie L, et al. Human miR-185* antisense nucleic acid and application thereof. 2011. (CN102140468A)
   Google Scholar
• Kan D, Peizuo Z, Jie L, et al. Human miR (microRNA)-1296 antisense nucleic acid and application thereof. 2011. (CN102140463A)
   Google Scholar
• Kan D, Peizuo Z, Jie L et al. Human miR-145 antisense nucleic acid and application thereof. 2012. (CN102382824A)
   Google Scholar
• Kan D, Peizuo Z, Jie L et al. Human miR-328 antisense nucleic acid and application thereof. 2012. (CN102533755A)
   Google Scholar
• Kan D, Peizuo Z, Jie L et al. Human miR-486-5p antisense nucleic acid and application thereof. 2013. (CN102041256B)
   Google Scholar
• Shi Z, Chunsheng K, Junxia Z et al. Small molecule inhibitors of miR-21 and Application. 2016. (CN103044338B).
   Google Scholar
• Leedman P, Giles K, Webster RJ. Procedure for modulating expression of epidermal growth factor receptor (EGFR) concerning miRNA. 2015. (DK2061482T3).
   Google Scholar
• Krichevsky AM, El-Fatimy R, Uhlmann EJ. Genome Editing for Treating Glioblastoma. 2017. (WO2017123910A1)
   Google Scholar
• Allerson CR MicroRNA compounds and methods for modulating miR-10b activity. 2020. (WO2020102142A1).
   Google Scholar
• Wang S. Application of anti-sense miRNA (Ribonucleic Acid)-210 to preparation of anti-cancer drug. 2012. (CN102475892A).
   Google Scholar
• Chunping J, Junhua W. Application of microRNA-29a in preparing medicine for inhibiting glioma invasion and metastasis. 2015. (CN104306997A)
   Google Scholar
• Xing G, Gang L, Hong L, et al. Application of microRNA-29a-3p as glioma blood vessel mimesis control target spot. 2020. (CN110946873A)
   Google Scholar
• Clarke MF, Hass AT. Cancer stem cells. Rev Cell Biol Mol Med. RA Meyers, editor. 2006. p. 221–41
   Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–111.
   PubMed Web of Science ®Google Scholar
• Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66(9):4553–4557.
   PubMed Web of Science ®Google Scholar
• Wang B, Bian X, Wang Z et al. Application of miRNA-106a and miRNA-106a inhibitor in preparing glioblastoma stem cell invasion regulator. 2012. (CN102321585B).
   Google Scholar
• Chiou S-H, Hsu H-S, Cherng J-Y. Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microRNA145. 2014. (US8846633B2).
   Google Scholar
• Ting S, Wei Y. Application of miRNA-153 in preparation of glioma stem cell radiosensitizing agent. 2015. (CN104840974B).
   Google Scholar
• Sampath P. Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomiR-138. 2017. (EP2654801B1).
   Google Scholar
• Jing S, Mingfei L. Application of small molecule RNA hsa-miR-874 in the tumor medicament for the treatment of glioblastoma. 2018. (CN105412140B).
   Google Scholar
• Kim I-A, Cho B-J, Choi E-J, et al. Modulation of radiation response using microRNA. 2015. (US8980863B2).
   Google Scholar
• Park JB, Lee SH, Kwak HJ, et al. Composition containing microRNA-21 inhibitor for enhancing radiation sensitivity. 2014. (US8883751B2)
   Google Scholar
• Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3):28.
   PubMed Web of Science ®Google Scholar
• Carbone JE, Ohm DP. Immune dysfunction in cancer patients. Oncol (Huntingt). 2002;16(1 suppl 1):11–18.
   PubMed Web of Science ®Google Scholar
• Sidler D, Renzulli P, Schnoz C, et al. Colon cancer cells produce immunoregulatory glucocorticoids. Oncoimmunology. 2012;1(4):529–530.
   PubMed Web of Science ®Google Scholar
• Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2(1):59–64.
   PubMed Web of Science ®Google Scholar
• Holmstrøm K, Pedersen AW, Claesson MH, et al. Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. Hum Immunol. 2010;71(1):67–73.
   PubMed Web of Science ®Google Scholar
• Romano G, Kwong LN. Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metast Rev. 2018;37(1):45–53.
   PubMed Web of Science ®Google Scholar
• Heimberger A, Wei J. miRNA for treating cancer and for use with adoptive immunotherapies. 2017. (US9675633B2).
   Google Scholar
• Okada H, Kohanbash G, Sasaki K. Th1-associated microRNAs and their use for tumor immunotherapy. 2013. (US8486911B2).
   Google Scholar
• Weiming F, Jinfang Z. MicroRNA for preparing a medicament to reduce the use of gliomas to TRAIL resistance. 2016. (CN103961720B).
   Google Scholar
• Shea A, Harish V, Afzal Z, et al. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016;5(8):1917–1946.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao D-Y, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–141.
   PubMed Web of Science ®Google Scholar
• Katakowski ME, Buller BAL, Chopp M. Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery. 2017. (US9555060B2).
   Google Scholar
• Rosin-Arbesfeld R, Sklan E, Zilberberg A, et al. miR-21 promoter driven targeted cancer therapy. 2013. (US8492133B2).
   Google Scholar
• Chunxiao W, Wang Shu, et al. Nucleic acid molecule and method of targeting gene expression to gliomas. 2011. (CN102099472A)
   Google Scholar
• Guocai G, Jia L, Leina M, et al. Adenovirus capable of expressing anti-cancer gene efficiently, regulated by miRNA and capable of specifically proliferating in glioma cells and application thereof. 2014. (CN103667347A)
   Google Scholar